However, several studies in SPTCL of all age groups previously showed that IST-based regimens can induce an excellent disease response in both HAVCR2-mutated and HAVCR2 wild-type groups [7, 16]. This evidence concerns the gene HAVCR2 and subcutaneous panniculitis-like T-cell lymphoma.